Novel Pharmacotherapies for L-DOPA-Induced Dyskinesia

[1]  G. Carrasco,et al.  Cannabinoid 2 receptors regulate dopamine 2 receptor expression by a beta-arrestin 2 and GRK5-dependent mechanism in neuronal cells , 2021, Neuroscience Letters.

[2]  A. Alhowail.  Molecular insights into the benefits of nicotine on memory and cognition , 2021, Molecular medicine reports.

[3]  Matthew D. Zammit,et al.  Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys , 2021, Nature Medicine.

[4]  J. Eckel,et al.  Cannabinoid Receptors in Metabolic Regulation and Diabetes. , 2021, Physiology.

[5]  S. George,et al.  Effects of daily Δ9-Tetrahydrocannabinol (THC) alone or combined with cannabidiol (CBD) on cognition-based behavior and activity in adolescent nonhuman primates. , 2021, Drug and alcohol dependence.

[6]  K. Murnane,et al.  The Endocannabinoid System and Alcohol Dependence: Will Cannabinoid Receptor 2 Agonism be More Fruitful than Cannabinoid Receptor 1 Antagonism? , 2021, CNS & neurological disorders drug targets.

[7]  A. Nambu,et al.  Abnormal Cortico-Basal Ganglia Neurotransmission in a Mouse Model of l-DOPA-Induced Dyskinesia , 2021, The Journal of Neuroscience.

[8]  M. Romero-Ramos,et al.  Periphery and brain, innate and adaptive immunity in Parkinson’s disease , 2021, Acta Neuropathologica.

[9]  S. Bufo,et al.  Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses , 2021, Toxins.

[10]  M. Previati,et al.  Relevance of Autophagy and Mitophagy Dynamics and Markers in Neurodegenerative Diseases , 2021, Biomedicines.

[11]  J. Fernández-Ruiz,et al.  Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis , 2021, British journal of pharmacology.

[12]  M. Assous.  Striatal cholinergic transmission. Focus on nicotinic receptors’ influence in striatal circuits , 2021, The European journal of neuroscience.

[13]  Gabriel Dias de Abreu,et al.  Contributive Role of TNF-α to L-DOPA-Induced Dyskinesia in a Unilateral 6-OHDA Lesion Model of Parkinson’s Disease , 2021, Frontiers in Pharmacology.

[14]  G. Oyama,et al.  New modalities and directions for dystonia care , 2021, Journal of Neural Transmission.

[15]  N. Mencacci,et al.  Emerging and converging molecular mechanisms in dystonia , 2021, Journal of Neural Transmission.

[16]  N. Chen,et al.  Research on developing drugs for Parkinson's disease , 2020, Brain Research Bulletin.

[17]  S. Bertini,et al.  Cannabinoid-Based Medicines and Multiple Sclerosis. , 2020, Advances in experimental medicine and biology.

[18]  D. Reddy,et al.  Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders. , 2020, Advances in experimental medicine and biology.

[19]  R. Franco,et al.  Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases. , 2020, Advances in experimental medicine and biology.

[20]  M. Kowalska,et al.  Oxidative stress factors in Parkinson’s disease , 2020, Neural regeneration research.

[21]  C. Tronel,et al.  Neuroprotective and anti-inflammatory effects of a therapy combining agonists of nicotinic α7 and σ1 receptors in a rat model of Parkinson’s disease , 2020, Neural regeneration research.

[22]  J. Schneider,et al.  A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease , 2020, Experimental Neurology.

[23]  Stephen L. Cowen,et al.  Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine , 2020, Experimental Neurology.

[24]  F. Guimarães,et al.  Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders , 2021, Frontiers in Pharmacology.

[25]  Yanan Sui,et al.  Deep Brain Stimulation Initiative: Toward Innovative Technology, New Disease Indications, and Approaches to Current and Future Clinical Challenges in Neuromodulation Therapy , 2021, Frontiers in Neurology.

[26]  Felipe Patricio,et al.  Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease , 2020, Frontiers in Pharmacology.

[27]  H. Reichmann,et al.  Parkinson’s disease and translational research , 2020, Translational Neurodegeneration.

[28]  Zhonghua Lu,et al.  Nicotine Prevents Oxidative Stress-Induced Hippocampal Neuronal Injury Through α7-nAChR/Erk1/2 Signaling Pathway , 2020, Frontiers in Molecular Neuroscience.

[29]  Wenli Wang,et al.  Protection by rhynchophylline against MPTP/MPP+-induced neurotoxicity via regulating PI3K/Akt pathway. , 2020, Journal of ethnopharmacology.

[30]  J. Fernández-Real,et al.  Nicotine' actions on energy balance: Friend or foe? , 2020, Pharmacology & therapeutics.

[31]  Steven McKnight,et al.  Toxin-Induced Parkinsonism. , 2020, Neurologic clinics.

[32]  M. Karpenko,et al.  Intranasal exposure of manganese induces neuroinflammation and disrupts dopamine metabolism in the striatum and hippocampus , 2020, Neuroscience Letters.

[33]  G. Zengin,et al.  Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions , 2020, International journal of molecular sciences.

[34]  P. Calabresi,et al.  Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities , 2020, Movement disorders : official journal of the Movement Disorder Society.

[35]  C. Suphioglu,et al.  Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review , 2020, Molecular Neurobiology.

[36]  Emily M Hahn,et al.  l-DOPA and consolidation of fear extinction learning among women with posttraumatic stress disorder , 2020, Translational Psychiatry.

[37]  M. Aschner,et al.  Nicotine and the nicotinic cholinergic system in COVID‐19 , 2020, The FEBS journal.

[38]  R. Hauser,et al.  Medical Management and Prevention of Motor Complications in Parkinson’s Disease , 2020, Neurotherapeutics.

[39]  R. Barker,et al.  Recent developments in the treatment of Parkinson's Disease , 2020, F1000Research.

[40]  Zhi-jie Liu,et al.  Structural and Functional Insights into Cannabinoid Receptors. , 2020, Trends in pharmacological sciences.

[41]  Penny A. MacDonald,et al.  Social Symptoms of Parkinson’s Disease , 2020 .

[42]  Stephen L. Cowen,et al.  Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia , 2020, Experimental Neurology.

[43]  O. Valverde,et al.  The Pro-neurogenic Effects of Cannabidiol and Its Potential Therapeutic Implications in Psychiatric Disorders , 2020, Frontiers in Behavioral Neuroscience.

[44]  J. Changeux,et al.  Do Nicotinic Receptors Modulate High-Order Cognitive Processing? , 2020, Trends in Neurosciences.

[45]  J. Steele,et al.  Severity of negative mood and anxiety symptoms occurring during acute abstinence from tobacco: A systematic review and meta-analysis , 2020, Neuroscience & Biobehavioral Reviews.

[46]  R. Shi,et al.  Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson’s disease through AKT/mTOR pathway , 2020, Aging.

[47]  Britta Hahn,et al.  Attention-enhancing effects of propranolol and synergistic effects with nicotine , 2020, Cognitive, Affective, & Behavioral Neuroscience.

[48]  J. Aasly,et al.  Clinical and Imaging Markers of Prodromal Parkinson's Disease , 2020, Frontiers in Neurology.

[49]  R. Moratalla,et al.  Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease , 2020, Neurobiology of Disease.

[50]  Shangjie Chen,et al.  Motor recovery and antidepressant effects of repetitive transcranial magnetic stimulation on Parkinson disease , 2020, Medicine.

[51]  C. Bardy,et al.  Genetic predispositions of Parkinson’s disease revealed in patient-derived brain cells , 2020, npj Parkinson's Disease.

[52]  O. Isacson,et al.  Advantages and Recent Developments of Autologous Cell Therapy for Parkinson’s Disease Patients , 2020, Frontiers in Cellular Neuroscience.

[53]  S. Fox,et al.  Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update , 2020, Expert opinion on emerging drugs.

[54]  A. Terry,et al.  α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future , 2020, Neuropharmacology.

[55]  Changliang Liu.  Targeting the cholinergic system in Parkinson’s disease , 2020, Acta Pharmacologica Sinica.

[56]  R. Papke,et al.  Nicotinic acetylcholine receptors: Conventional and unconventional ligands and signaling , 2020, Neuropharmacology.

[57]  J. Jankovic,et al.  Treatment of Tardive Dyskinesia. , 2020, Neurologic clinics.

[58]  B. Vissel,et al.  Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia , 2020, Neurobiology of Disease.

[59]  Patrik Brundin,et al.  Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. , 2020, Clinics in geriatric medicine.

[60]  A. Sanyaolu,et al.  Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes , 2020, Journal of Cannabis Research.

[61]  A. Grace,et al.  Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress , 2019, Behavioural Brain Research.

[62]  F. Guimarães,et al.  Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease , 2019, Neuropharmacology.

[63]  Qi Wang,et al.  Nicotine induced neurocognitive protection and anti-inflammation effect by activating α4β2 nAChRs in ischemic rats. , 2020, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[64]  P. Michel,et al.  Cannabidiol prevents LPS‐induced microglial inflammation by inhibiting ROS/NF‐κB‐dependent signaling and glucose consumption , 2020, Glia.

[65]  Thilo Womelsdorf,et al.  Dissociation of nicotinic α7 and α4/β2 sub-receptor agonists for enhancing learning and attentional filtering in nonhuman primates , 2019, Psychopharmacology.

[66]  F. Guimarães,et al.  Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson’s Disease and l-DOPA-Induced Dyskinesia , 2019, Neurotoxicity Research.

[67]  R. Shi,et al.  The Association of Iron and the Pathologies of Parkinson’s Diseases in MPTP/MPP+-Induced Neuronal Degeneration in Non-human Primates and in Cell Culture , 2019, Front. Aging Neurosci..

[68]  Yuko Fujita,et al.  MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling , 2019, Psychopharmacology.

[69]  Kimberly M Albert,et al.  Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study , 2019, Journal of Cancer Survivorship.

[70]  F. Guimarães,et al.  Biological bases for a possible effect of cannabidiol in Parkinson’s disease , 2019, Revista brasileira de psiquiatria.

[71]  Paolo Bonato,et al.  Gait impairments in Parkinson's disease , 2019, The Lancet Neurology.

[72]  G. Ebersbach,et al.  Evidence for the use of cannabinoids in Parkinson’s disease , 2019, Journal of Neural Transmission.

[73]  A. Tafreshi,et al.  Extended-Release Amantadine for Levodopa-Induced Dyskinesia , 2019, Expert review of neurotherapeutics.

[74]  G. Wenning,et al.  Iron in Neurodegeneration – Cause or Consequence? , 2019, Front. Neurosci..

[75]  A. Csoka,et al.  Nicotine protects against manganese and iron-induced toxicity in SH-SY5Y cells: Implication for Parkinson's disease , 2019, Neurochemistry International.

[76]  M. Quik,et al.  Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders. , 2018, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[77]  T. Bordia,et al.  Cholinergic control of striatal neurons to modulate L‐dopa‐induced dyskinesias , 2018, The European journal of neuroscience.

[78]  Zhiyun Wang,et al.  Association between dopamine receptor D2 TaqIA polymorphism and Parkinson disease risk: a meta-analysis. , 2019, International journal of clinical and experimental pathology.

[79]  A. Csoka,et al.  Novel targets for parkinsonism-depression comorbidity. , 2019, Progress in molecular biology and translational science.

[80]  D. Centonze,et al.  Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression , 2018, Front. Mol. Neurosci..

[81]  Faith L Anderson,et al.  Inflammasomes: An Emerging Mechanism Translating Environmental Toxicant Exposure Into Neuroinflammation in Parkinson's Disease. , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[82]  J. Changeux.  The nicotinic acetylcholine receptor: a typical ‘allosteric machine’ , 2018, Philosophical Transactions of the Royal Society B: Biological Sciences.

[83]  F. Carroll,et al.  Effect of nicotine and alpha‐7 nicotinic modulators on visceral pain‐induced conditioned place aversion in mice , 2018, European journal of pain.

[84]  W. Taylor,et al.  Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression , 2018, Neuroscience & Biobehavioral Reviews.

[85]  M. Sofuoglu,et al.  Cognitive Effects of Nicotine: Recent Progress , 2017, Current neuropharmacology.

[86]  S. Pandey,et al.  Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management , 2017, Annals of Indian Academy of Neurology.

[87]  C. Stary,et al.  Anesthetic neurotoxicity: an emerging role for glia in neuroprotection , 2017, Journal of Molecular Medicine.

[88]  M. Aschner,et al.  Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese. , 2017, EC pharmacology and toxicology.

[89]  Y. Tizabi,et al.  Nicotinic Receptor Intervention in Parkinson's Disease: Future Directions. , 2017, Clinical pharmacology and translational medicine.

[90]  M. Aschner,et al.  “Manganese-induced neurotoxicity: a review of its behavioral consequences and neuroprotective strategies” , 2016, BMC Pharmacology and Toxicology.

[91]  F. Guimarães,et al.  Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action , 2016, Neurobiology of Disease.

[92]  J. Jankovic,et al.  Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia , 2016, Drugs.

[93]  S. Sherman,et al.  Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing l-DOPA-Induced Dyskinesias , 2016, Case Reports in Neurology.

[94]  Y. Tizabi.  Duality of Antidepressants and Neuroprotectants , 2016, Neurotoxicity Research.

[95]  J. Pilz,et al.  Use and effects of cannabinoids in military veterans with posttraumatic stress disorder. , 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[96]  B. Chakrabarti,et al.  Endocannabinoid Signaling in Autism , 2015, Neurotherapeutics.

[97]  J. A. Dani,et al.  Neuronal Nicotinic Acetylcholine Receptor Structure and Function and Response to Nicotine. , 2015, International review of neurobiology.

[98]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.